Subject: In-Practice Usage and Performance (IPUP) Study of Prohance; Study code: Classic /IPUP/Prohance/2023Oral nutrition supplement (ONS) is nutritional supplement for disease-related mal-nutrition.

These nutritional supplement products can partially, or wholly, replace a normal diet to provide patients with the essential nutrients they need when food alone is insufficient to meet their daily needs. The NICE (National Institute for Health and Care Excellence) Quality Standard on Nutrition Support in Adults, recognizes that ONS is clinically effective way to manage disease-related malnutrition. It is important that nutrition support goes beyond just providing insufficient calories and looks to provide all the relevant nutrients that should be contained in a nutritionally complete diet. A management care plan aims to provide that and identifies condition insufficient circumstances and associated needs linked to nutrition support requirements Prohance, a balanced nutritional energy supplement powder is marketed by the 'Classic' team of Sun Pharmaceutical Industries Ltd.

Although every product is marketed only after regulatory approval, it is important to know how it performs in day-to-day practice of individual medical practitioners.

For this purpose, we have planned to conduct a prospective study to assess the real-life performance of Prohance in patients.

We invite you to participate in this study. Requesting you to report on a standard form your experience with 'Prohance' in {{$numberOfPatient}} patients in whom you prescribe this product in the normal course of your practice. This is not an experimental study because the product will be prescribed and purchased, as you and your patient's normally do.

If you agree to participate, you will need to copy the relevant information from the suggested number of patient's case papers on to the standard case report forms. Let us assure you that the CRF will not contain the patients' names, so as to ensure confidentiality. If any serious adverse events (AE) occur during this supplementation, you will be expected to report them to us immediately on the AE reporting form.

As you will be spending some extra time to keep, copy and verify these patient's records, we offer to pay you by cheque a professional fee of Rs. {{$contractAmount}}/- .

We trust you and we are partners in promoting safe and effective drug therapy. In that spirit, we hope you will provide consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.